8 results
In deze studie zal de nauwkeurigheid van peroperatieve meting van de cuppositie door een nieuw ontworpen, onlangs gepatenteerd, meetinstrument worden onderzocht. In de toekomst kan, indien het meetinstrument betrouwbaar blijkt, peroperatief de…
To compare tumor [11C]erlotinib pharmacokinetics in NSCLC patients with and without erlotinib therapy. Also, to assess the relationship of venous sampling versus arterial, of tumor [11C]erlotinib uptake and blood flow with and without therapy, and…
Primary Objective: To study the tumour pharmacokinetics of [11C]erlotinib in NSCLC patients in vivo and relating uptake with EGFR mutations, obtained from tumour biopsies. Secondary Objective(s): 1. to define the test-retest reproducibility of [11C]…
To evaluate interlesional and intralesional differences in [11C]erlotinib uptake in EGFR mutated (EGFR+) NSCLC patients who are at different stages in their TKI treatment. To correlate tumor [11C]erlotinib uptake to EGFR mutational status, tumor…
The primary objective of this study is to demonstrate the efficacy of fremanezumab in the prevention of CCH in adult patients:- The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the monthly average…
As of 15 June 2018, only patients from the ECH study (Study TV48125 CNS 30056) will enroll in this study for active treatment. As of 15 June 2018, all CCH patients included in this study have been asked to discontinue treatment, and are encouraged…
The primary objective of this study is to demonstrate the efficacy of fremanezumab in the prevention of ECH in adult patients. The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the weekly average number…
The primary objective of the study is to demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult patients with migraine with inadequate response to 2 to 4 classes of prior preventive…